ESG reporting: Hang Seng companies have transparency shortcomings

HONG KONG, Dec 15, 2022 – (ACN Newswire via SEAPRWire.com) – Companies in the Hang Seng Index rank in the midrange internationally in terms of the quality of their ESG reporting. This is the finding of the Global ESG Monitor 2022 (GEM), Regional Report Hong Kong/China (https://globalesgmonitor.com/download-report/), published today. The GEM is considered an international […]

Nissin Foods Announces 2022 Q3 Results

HONG KONG, Nov 10, 2022 – (ACN Newswire via SEAPRWire.com) – Nissin Foods Company Limited (“Nissin Foods” or the “Company”, and together with its subsidiaries, the “Group”; Stock code: 1475) today announced its financial results for the nine months ended 30 September 2022 (“the Reporting Period”). Revenue of the Group increased solidly by 7.8% year-on-year […]

Nissin Foods Wins Bid for Acquiring Equity Interest in Zhuhai Winner at RMB352.44 Million

HONG KONG, Nov 7, 2022 – (ACN Newswire via SEAPRWire.com) – Nissin Foods Company Limited (“Nissin Foods”, and together with its subsidiaries, the “Group”; Stock code: 1475) announced that its wholly-owned subsidiary Nissin Foods (China) Holding Co., Ltd. (“Nissin Foods China”) has won a bid for 29.55% equity interest in Zhuhai Golden Coast Winner Food […]

China Risun’s 2022 Interim Revenue Ups 21.1% to RMB22.53 Billion, Profit Attributable to Owners was RMB1.74 Billion

HONG KONG, Aug 29, 2022 – (ACN Newswire via SEAPRWire.com) – China Risun Group Limited (“China Risun”, or the “Group”, stock code: 1907), a leading global integrated coke, coking chemicals and refined chemicals producer and supplier and relevant operation management services provider in China, has announced its interim results for the six months ended 30 […]

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion

HONG KONG, Aug 23, 2022 – (ACN Newswire via SEAPRWire.com) – Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited Interim results for the six months ended 30 June 2022 (the “Period”). Development Highlights— The Group achieved […]